mitomycin has been researched along with Carcinoma, Papillary in 31 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 9.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ." | 9.08 | A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. ( Debruyne, FM; Doesburg, WH; van der Meijden, AP; Vegt, PD; Witjes, JA; Witjes, WP, 1995) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 9.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 9.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation." | 9.06 | Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. ( Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1987) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 7.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression." | 7.67 | Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. ( Alfthan, O; Jauhiainen, K, 1987) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 6.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 5.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ." | 5.08 | A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. ( Debruyne, FM; Doesburg, WH; van der Meijden, AP; Vegt, PD; Witjes, JA; Witjes, WP, 1995) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 5.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 5.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation." | 5.06 | Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. ( Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1987) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 3.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression." | 3.67 | Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. ( Alfthan, O; Jauhiainen, K, 1987) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 2.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | 2.66 | Approaches to the treatment of bladder cancer at Stanford. ( Torti, FM, 1987) |
| "In 41 cases of primary breast cancer preoperative treatment was performed using 2 methods consisting CPA + FT-207 (5-FUDS) (for Group I) and CPA + FT-207 (5-FUDS) + MMC (for Group II) to determine clinical and histological efficacies." | 1.27 | [Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC]. ( Andoh, H; Fujii, Y; Gotoh, M; Hagiwara, H; Hara, Y; Kataoka, J; Kobayashi, T; Komuro, K; Nagasaki, Y; Nagayama, A; Nakamura, K; Nakamura, R, 1983) |
| "Although experimental induction of bladder cancer with powerful carcinogens may completely overwhelm host defenses and result in more and higher grade neoplasms, similar tumors may occur after exposure to substances not generally considered to be carcinogenic." | 1.27 | Bladder cancer induced by noncarcinogenic substances. ( Akaza, H; Murphy, WM; Soloway, MS, 1984) |
| " Intra-arterial chemotherapy combined with MMC and DSM was performed on eight cases of unresectable metastatic liver carcinoma." | 1.27 | [Intra-arterial chemotherapy combined with mitomycin C and degradable starch microspheres in unresectable metastatic liver carcinoma]. ( Arai, K; Awane, Y; Kitamura, M; Mori, T; Takahashi, T; Yoshikawa, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (51.61) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 2 (6.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arends, TJ | 1 |
| Nativ, O | 1 |
| Maffezzini, M | 1 |
| de Cobelli, O | 1 |
| Canepa, G | 1 |
| Verweij, F | 1 |
| Moskovitz, B | 1 |
| van der Heijden, AG | 1 |
| Witjes, JA | 2 |
| El-Ghobashy, S | 1 |
| El-Leithy, TR | 1 |
| Roshdy, MM | 1 |
| El-Ganzoury, HM | 1 |
| Fradet, Y | 1 |
| Böhle, A | 1 |
| Bock, PR | 1 |
| Altieri, V | 1 |
| Bartoletti, R | 1 |
| Cai, T | 1 |
| Mondaini, N | 1 |
| Farina, U | 1 |
| Melone, F | 1 |
| Mazzoli, S | 1 |
| Gontero, P | 1 |
| Komuro, K | 1 |
| Hara, Y | 1 |
| Fujii, Y | 1 |
| Nagayama, A | 1 |
| Kobayashi, T | 1 |
| Gotoh, M | 1 |
| Hagiwara, H | 1 |
| Nakamura, R | 1 |
| Nagasaki, Y | 1 |
| Kataoka, J | 1 |
| Andoh, H | 1 |
| Nakamura, K | 1 |
| Friedell, GH | 1 |
| Akaza, H | 1 |
| Murphy, WM | 2 |
| Soloway, MS | 3 |
| Vegt, PD | 1 |
| Witjes, WP | 1 |
| Doesburg, WH | 2 |
| Debruyne, FM | 4 |
| van der Meijden, AP | 2 |
| Mulders, PF | 1 |
| Meyden, AP | 1 |
| Oosterhof, GO | 1 |
| Boccardo, F | 1 |
| Cannata, D | 1 |
| Rubagotti, A | 1 |
| Guarneri, D | 1 |
| Decensi, A | 1 |
| Canobbio, L | 1 |
| Curotto, A | 1 |
| Martorana, G | 1 |
| Pegoraro, C | 1 |
| Selvaggi, F | 1 |
| Kaasinen, E | 2 |
| Rintala, E | 2 |
| Pere, AK | 1 |
| Kallio, J | 1 |
| Puolakka, VM | 1 |
| Liukkonen, T | 1 |
| Tuhkanen, K | 1 |
| Fukui, I | 2 |
| Kihara, K | 2 |
| Sekine, H | 2 |
| Tachibana, Y | 1 |
| Kawai, T | 2 |
| Ishiwata, D | 2 |
| Oshima, H | 1 |
| Droller, MJ | 1 |
| Flanigan, RC | 1 |
| Nseyo, UO | 1 |
| Hellsten, S | 1 |
| Månsson, W | 1 |
| Henrikson, H | 1 |
| Idwall, I | 1 |
| Lindholm, K | 1 |
| Mikulowski, P | 1 |
| Mårtensson, S | 1 |
| Oldbring, J | 1 |
| Jauhiainen, K | 2 |
| Ruutu, M | 1 |
| Alfthan, O | 2 |
| Trybula, M | 1 |
| King, M | 1 |
| Torti, FM | 1 |
| van der Meijden, PM | 1 |
| Steerenberg, PA | 1 |
| de Jong, WH | 1 |
| Doesburg, W | 1 |
| Franssen, MP | 1 |
| Milani, C | 1 |
| Bassi, PF | 1 |
| Meneghini, A | 1 |
| Giunta, A | 1 |
| Tejerizo, JC | 1 |
| dal Bianco, M | 1 |
| Zattoni, F | 1 |
| Garbeglio, A | 1 |
| Blatnik, AF | 1 |
| Shelton, TB | 1 |
| Yamada, T | 1 |
| Washizuka, M | 1 |
| Oka, K | 1 |
| Hosoda, K | 1 |
| Ikegami, S | 1 |
| Tsushima, T | 1 |
| Matsumura, Y | 1 |
| Ozaki, Y | 1 |
| Yoshimoto, J | 1 |
| Ohmori, H | 1 |
| Kawano, S | 1 |
| Yano, S | 1 |
| Sakamoto, S | 1 |
| Ogata, J | 1 |
| Ferraris, V | 1 |
| Arai, K | 1 |
| Mori, T | 1 |
| Kitamura, M | 1 |
| Yoshikawa, T | 1 |
| Takahashi, T | 1 |
| Awane, Y | 1 |
| Stachura, J | 1 |
| Popiela, T | 1 |
| Pietroń, M | 1 |
| Tomaszewska, R | 1 |
| Kulig, J | 1 |
| Nowak, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)[NCT00384891] | Phase 3 | 190 participants (Actual) | Interventional | 2002-02-28 | Terminated (stopped due to slow accrual) | ||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitomycin and Carcinoma, Papillary
| Article | Year |
|---|---|
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 2004 |
15 trials available for mitomycin and Carcinoma, Papillary
| Article | Year |
|---|---|
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2016 |
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Carcinoma, Tran | 2007 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Follow-Up Studie | 1995 |
Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Carcin | 1994 |
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillar | 1994 |
Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplas | 2000 |
Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 1992 |
Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papi | 1990 |
Approaches to the treatment of bladder cancer at Stanford.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcin | 1987 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Cystitis; Humans | 1989 |
BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clini | 1989 |
[Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Papillary; Clinical Trials as Topic; Dru | 1989 |
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 1987 |
Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Carcinoma, Papillary; Clinical Trials as Topic; Combined Modality Ther | 1987 |
15 other studies available for mitomycin and Carcinoma, Papillary
| Article | Year |
|---|---|
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro.
Topics: Antibiotics, Antineoplastic; Carcinoma, Papillary; Cost-Benefit Analysis; Cystoscopy; Humans; Mitomy | 2012 |
[Fixed points and open questions in the treatment of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Papillary; Humans; Mito | 2006 |
[New therapeutics in the suppression of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Agmatine; Antimetabolites, Antineoplasti | 2006 |
[Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 1983 |
Bladder cancer induced by noncarcinogenic substances.
Topics: Administration, Topical; Animals; Carcinoma, Papillary; Cisplatin; Female; Hyperplasia; Mitomycin; M | 1984 |
Superficial bladder disease: case studies and therapeutic advances.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Ca | 1992 |
Intravesical mitomycin C for carcinoma in situ of the urinary bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillary; Comb | 1990 |
Superficial bladder cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Doxorubici | 1985 |
Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters.
Topics: Animals; Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Transitional Cell; Catheters, Indwellin | 1986 |
Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Papillary; Doxorubicin; Fem | 1987 |
Effect of continuous intravesical infusion of low-concentrated mitomycin-C on bladder carcinogenesis in rats treated with N-butyl-N-4-hydroxybutyl-nitrosamine.
Topics: Administration, Intravesical; Animals; Butylhydroxybutylnitrosamine; Carcinoma, Papillary; Carcinoma | 1988 |
Doxorubicin plus mitomycin C regimen in the prophylactic treatment of superficial bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 1988 |
[Intra-arterial chemotherapy combined with mitomycin C and degradable starch microspheres in unresectable metastatic liver carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Papillary; Combined Modality Therapy; Embolization, Therapeu | 1988 |
Cytology of solid and papillary epithelial neoplasms of the pancreas: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Papillary; Cytodia | 1988 |